Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Here's a recap of the week’s most important stories.

Wall Street staged a cautious comeback in the wake of a Treasury selloff that shook markets around the globe amid fiscal ...

Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss ...

Wall Street showed signs of stabilization just a day after a Treasury selloff that shook markets around the globe, with stocks seeing small moves amid a rebound in bonds from session lows. The dollar ...

Blood and urine tests might be able to reveal how much of your diet is made up of industrially produced foods, a new study ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...